🇺🇸

US SEC Filing Intelligence

· daily

Global High-Priority Regulatory Events — July 31, 2026

The July 31, 2026, filings reveal a market bifurcated between aggressive M&A-driven growth and distress signals. A wave of Nasdaq delisting notices (Electro Sensors, Community First, and multiple biotech/pharma companies) highlights a liquidity crunch among small-caps, while major strategic acquisitions (Amazon-Globalstar, Deluxe-Celero) signal continued appetite for transformative deals. Indian filings show robust earnings growth (GAIL +127.5% YoY, Leela Palaces +74.5% YoY) but also significant insolvency events (TV Vision, Siti Networks) and governance lapses. SPAC activity is mixed, with some extensions and some liquidations. Key themes include aggressive capital deployment, regulatory enforcement in India, and a rising tide of going-concern risks for micro-caps.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 31, 2026

The July 31, 2026 filings reveal a market characterized by strong top-line growth in technology and gold mining, but with significant margin pressures and rising costs across industrials and financials. Apple's 27% net income surge and Sony's 40% operating income jump highlight robust consumer tech demand, while gold miners like AngloGold Ashanti and Buenaventura benefit from record gold prices, though cost inflation is a persistent headwind. A notable divergence is emerging between companies successfully passing through costs (Apple, Sony) and those seeing margin compression (ASGN, LendingTree). Capital allocation remains active, with buybacks at Sierra Bancorp, a major acquisition at Neurocrine, and a SPAC merger for BIG3, while insider activity is mixed—a complete exit by a major shareholder in Sanara MedTech contrasts with a small insider loan at BTCS Labs. The most critical developments include the BIG3 SPAC merger at a $290M valuation, the Kumamoto earthquake risk for Sony, and the ongoing proxy fight at XAI Octagon. Portfolio-level patterns show a rotation into gold and alternative assets, with institutional filings (ARGA, Aviance) revealing heavy concentration in mega-cap tech and Latin American financials.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 31, 2026

The six filings reveal a bifurcated Consumer Discretionary landscape. Amazon is executing a transformative satellite acquisition (Globalstar) while reporting a massive Q2 earnings beat, though its cash burn from capex is accelerating. Chipotle shows a classic growth-at-all-costs warning: revenue up 9% YoY but operating income down 6%, with cost inflation and aggressive buybacks eroding retained earnings. General Motors' insider activity (VP tax-withholding sale of $4.36M) is routine, but its 13F signals a deepening vertical integration bet on battery materials and EV charging. eBay's passive stake drop below 5% by Vanguard is a minor sentiment shift. The dominant portfolio-level themes are margin compression despite top-line growth, heavy capital allocation toward strategic M&A and buybacks, and rising leverage across the sector.

4 high priority 2 medium 6 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 31, 2026

The S&P 500 Healthcare sector is presenting a mixed picture for Q2 2026, characterized by strong top-line growth at major medical device and diversified pharma companies, contrasted with significant challenges in the biotech and specialty pharma segments. Stryker and Thermo Fisher delivered robust double-digit revenue growth, while AbbVie showed strong core growth driven by immunology and neuroscience, offset by continued Humira erosion. However, Moderna faces a deteriorating cash position and a failed Phase 3 trial, while Amgen disclosed a material cybersecurity breach. A key portfolio-level trend is the aggressive capital deployment for M&A and share buybacks, which is pressuring balance sheets and cash positions across the group. Insider activity was limited but negative at Intuitive Surgical, while forward-looking statements from AbbVie and Moderna point to divergent paths, with AbbVie guiding higher and Moderna struggling to stabilize. The sector is bifurcated between established growth engines and companies facing pipeline or operational headwinds.

5 high priority 2 medium 7 total filings
· daily

US Earnings Financial Results SEC Filings — July 31, 2026

The 50 filings for the period ending July 31, 2026, reveal a bifurcated market where top-line growth is often not translating to bottom-line expansion. A clear theme is 'growth at a cost,' with 12+ companies reporting revenue increases but margin compression or net income declines due to rising operating expenses, interest costs, and acquisition-related charges. The financial sector shows strong earnings momentum, led by Bank of America (+26.5% net income) and Truist (+25.2%), driven by higher noninterest income and lower provisions, though regional banks like Amerant (-8.5%) face net interest margin compression. Technology and asset managers present a mixed picture: Apple (+27% net income) and Amazon (surge from non-operating gains) outperform, while Houlihan Lokey (-20.4%) and ASGN (-51.5%) struggle. A notable capital allocation trend is aggressive share repurchases, with Roper ($2.7B), AutoNation ($469.7M), and GoDaddy ($558.6M) buying back significant stock, often funded by debt. Insider trading data is sparse, but the lack of insider buying amidst heavy buybacks may signal management sees limited internal reinvestment opportunities. The most critical developments include the liquidation of Elme Communities, a sharp turnaround at Procore Technologies (from -$21.1M loss to +$16.9M profit), and a massive $53.4B non-operating gain at Amazon, which masks underlying operational cash flow pressures from heavy capex.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 31, 2026

This intelligence digest covers 12 pre-analyzed US SEC proxy filings, primarily focused on executive compensation, governance, and shareholder voting proposals. A dominant theme is corporate control events: three filings (RF Acquisition Corp II, AstroNova, Crinetics Pharmaceuticals) involve critical shareholder votes on M&A transactions or business combination deadlines, with AstroNova and Crinetics presenting high-premium cash offers ($29.00 and $85.00 per share, respectively) that offer immediate exit liquidity. Insider alignment is strongly evident in the controlled structures of Interparfums (43.5% insider ownership) and FibroBiologics (CEO controls ~20% of votes via preferred stock), ensuring management and shareholder interests are linked. Several micro-cap and pre-revenue biotech companies (Aptevo, Vistagen, Netlist) show low materiality with standard governance proposals and no material operational updates, signaling a focus on corporate survival rather than growth. No significant period-over-period comparisons (revenue, margins) or forward-looking guidance changes were present across the filings, as these proxy statements do not contain financial results. Key scheduled events include concentrated voting periods in late August to mid-September 2026, with critical M&A-related special meetings at AstroNova (Aug 25) and Crinetics (Aug 28). The overall sentiment across filings is neutral, with materiality ranging from low (routine director elections) to very high (binding M&A votes and share issuance proposals).

12 high priority 12 total filings
· daily

USA Institutional Investor Activity — July 31, 2026

The two 13F filings for the period ended June 30, 2026, reveal a bifurcated institutional landscape: ZEGA Investments, LLC employs an active, tactical strategy with mixed sentiment, combining large outright long positions in mega-cap tech (Apple, Amazon, Alphabet) with extensive options hedging, while BCS Private Wealth Management, Inc. presents a more static, income-oriented snapshot with outsized holdings in fixed-income ETFs and a notable speculative position in Oscar Health. No period-over-period comparisons, forward-looking statements, or insider trading data are available from either filing, limiting trend analysis. The key takeaway is the divergence in institutional approach—one manager is actively hedging against volatility, while the other appears to be building yield and event-driven exposure. The lack of comparative data makes it impossible to assess portfolio-level growth or margin trends, but the presence of large option positions at ZEGA suggests elevated hedging activity, potentially signaling near-term market uncertainty. The most actionable insight is the outsized position in Oscar Health by BCS, which could indicate a concentrated bet on the healthcare sector's regulatory or earnings catalyst.

2 medium 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 31, 2026

All 8 filings in this digest involve Nasdaq-listed companies receiving deficiency notices for failing to maintain the minimum $1.00 bid price per share over 30 consecutive business days, signaling a concentrated wave of micro-cap distress. The filings cluster around late July 2026, with compliance deadlines in late January 2027, and most companies are exploring reverse stock splits as a potential cure. Notably, bioAffinity Technologies faces an accelerated delisting risk due to a prior reverse split, while DocGo has already secured an additional 180-day grace period. No period-over-period financial trends, insider transactions, or capital allocation data were provided in the enriched filings, limiting quantitative cross-company comparisons. The overarching theme is a sector-wide liquidity and valuation crisis among small-cap biotech and healthcare firms, with no immediate trading halts but significant delisting overhangs. The market implication is heightened volatility and potential forced delistings for companies unable to execute timely reverse splits or attract buying interest.

8 high priority 8 total filings
· daily

US Executive Officer Management Changes SEC — July 31, 2026

The July 31, 2026, digest reveals a significant wave of leadership transitions across 30 filings, with a notable concentration of CEO and CFO departures, often tied to strategic shifts, M&A activity, or cost restructuring. Key period-over-period trends from the enriched data show a mixed picture: Standex International posted strong organic growth of 7.7% YoY with record margins, while ChargePoint's restructuring signals ongoing cost pressures, reaffirming flat revenue guidance. The most critical development is the conditional resignation of Quince Therapeutics' entire C-suite, contingent on shareholder approval for a transformative acquisition, representing a high-stakes governance event. Portfolio-level patterns include a rise in routine board departures due to external policies, and a trend of internal promotions for key roles, suggesting a focus on continuity. Insider activity is sparse but notable, with no major buying or selling detected, while forward-looking data highlights key catalyst dates in September 2026 for shareholder votes and executive transitions.

30 high priority 30 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 31, 2026

The July 31, 2026, digest of 30 SEC filings reveals a period of significant board and C-suite restructuring across multiple sectors, with a notable concentration of leadership changes in the mining, energy, and technology industries. While many changes are routine retirements or policy-driven resignations, several filings signal deeper strategic shifts, including a conditional CEO/CFO/COO overhaul at Quince Therapeutics tied to a major acquisition, and a simultaneous CFO and director resignation at Arrive AI without named successors. Period-over-period financial data from Standex International shows strong organic growth (7.7% YoY) and record margins, contrasting with a 10% workforce reduction at ChargePoint Holdings, which is reaffirming lowered guidance. Insider trading activity was minimal in this batch, but capital allocation trends include a significant share authorization increase at Greater Cannabis Company (from 300M to 600M shares) and an equity plan expansion at Milestone Scientific, both potential dilution risks. The overall sentiment is mixed, with a bias toward neutral governance adjustments, but with several high-materiality events (Quince, ChargePoint, Standex) that warrant close monitoring for portfolio impact.

30 high priority 30 total filings
· daily

USA Insider Trading Pulse — July 31, 2026

Today's insider trading filings reveal a pronounced bearish tilt, with 14 distinct sell transactions by C-suite executives and directors totaling over $10.5 million, contrasted by only 2 modest open-market purchases. The most significant insider sales occurred at Royal Caribbean Cruises ($4.05M by a President/CEO), General Motors ($4.36M tax-withheld vesting), and Ecolab ($930K by CFO), signaling potential top-side caution at these large caps. However, a strong counter-narrative of insider confidence emerges at Diebold Nixdorf and Kingsway Financial Services, where CFOs and CEOs are buying shares with personal cash, a rare and bullish signal. The data is dominated by routine equity awards and option exercises, which are neutral, but the concentration of high-value, open-market sales by key officers warrants close attention. The lack of any positive forward-looking guidance or upward earnings revisions in this batch amplifies the cautious tone, suggesting that insiders are using current market strength to reduce exposure.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 31, 2026

The USA M&A & Takeover Activity stream for July 31, 2026, reveals a market bifurcated between transformative, high-value deals and a wave of SPAC distress. Deluxe Corp's acquisition of Celero Commerce stands out as a high-conviction, accretive deal with clear synergy targets and a catalyst calendar, while several SPACs face existential risks: Agriculture & Natural Solutions Acquisition Corp is liquidating, Columbus Acquisition Corp is at risk of delisting, and Digital Asset Acquisition Corp postponed its shareholder vote. The period-over-period data is limited as most filings are event-driven 8-Ks without financial statements, but forward-looking statements and scheduled events provide actionable catalysts. Insider activity is absent across all filings, a notable gap that limits conviction signals. Capital allocation trends show a mix of SPAC IPOs raising $291 million in fresh capital versus liquidation and redemption events. The overall theme is one of selective opportunity in high-quality deals and caution in the SPAC space, where time is running out for many blank-check companies.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 31, 2026

Overnight filings from July 30-31, 2026, reveal a market bifurcated between strong operational performance and cautious insider behavior. Apple Inc. delivered a standout quarter with net income surging 27% YoY to $29.8B, while Sony Group and AngloGold Ashanti also reported robust top-line growth, though Sony flagged a potential slowdown with nearly flat full-year guidance. Insider selling was a dominant theme, with the CEO of Tempus AI and the Co-Chairman of Charles Schwab each selling over $10M in stock, signaling potential concerns about valuation or near-term outlook. Conversely, insider buying at Navios Maritime Partners, though small in size, offers a contrarian positive signal. Capital allocation trends are mixed: Sierra Bancorp increased its dividend while repurchasing shares, but Waton Financial's net loss widened despite a 49% revenue surge, highlighting a disconnect between growth and profitability. The gold sector is a key theme, with AngloGold Ashanti's 44% revenue surge and NOVAGOLD's merger announcement reflecting strong investor appetite for precious metals amid a $4,200/oz gold price. Overall, the data suggests a market where revenue growth is common, but margin pressure, insider selling, and cautious forward guidance warrant a selective, quality-focused approach.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 30, 2026

The S&P 500 Technology sector is showing a tale of two narratives: a large-cap giant (Apple) reporting mixed results with record top-line growth but margin headwinds from tariff impacts, contrasted with a high-growth cybersecurity firm (Fortinet) delivering accelerating product sales and strong profitability, albeit with a deteriorating equity base from aggressive buybacks. A key bearish signal from the insider trading activity at CrowdStrike, where the CEO sold nearly $600k worth of shares under a 10b5-1 plan, introduces caution into the otherwise positive sector sentiment. Portfolio-level insights reveal a bifurcation in growth drivers: Apple relies on iPhone and Services (double-digit growth) while facing a 6% YoY decline in iPad, whereas Fortinet's product revenue surged 51.9% YoY. A common theme is the heavy use of capital returns (Apple's robust buyback, Fortinet's $972.8M in H1 repurchases), but Fortinet's transition to an accumulated deficit raises a red flag. The upcoming catalyst calendar is sparse, with no specific earnings calls noted, but the CrowdStrike insider selling pattern warrants close monitoring.

3 high priority 3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 30, 2026

The July 30, 2026 batch of NASDAQ-100 filings reveals a market bifurcated between AI-driven growth and the heavy costs of that investment. Mega-cap leaders like Amazon and Meta reported strong top-line growth (20% and 28% YoY, respectively), but both saw significant cash flow deterioration due to massive AI capex, with Amazon's free cash flow turning negative (-$7.6B) and Meta's cash reserves halving. Apple delivered a record quarter with 16% revenue growth, though its margin was artificially boosted by tariff refunds. In contrast, the crypto-exposed sector showed extreme volatility: Strategy Inc swung from a $10B profit to an $8.2B loss on digital asset revaluations, while Lite Strategy executed a successful NAV-discount-reducing buyback. Insider activity was a notable bearish signal, with a CEO and a Principal Accounting Officer at CoreWeave selling a combined $6.7M, alongside smaller sales at Booking, Alphabet, and PayPal. The overall picture is one of aggressive capital deployment into AI and digital assets, creating winners in revenue growth but raising red flags on cash flow sustainability and insider conviction.

8 high priority 7 medium 15 total filings
· daily

VA Healthcare & Services Contracts — July 30, 2026

This digest covers nine VA healthcare contracts awarded on July 28, 2026, totaling $6.49 billion in obligations, all from the Department of Veterans Affairs with zero defense-related content. Every contract went to UnitedHealth Group subsidiary Optum Public Sector Solutions, creating extreme single-recipient concentration risk. The contracts are all firm-fixed-price delivery orders with one-month performance periods (January–March 2026) and zero outlayed funds, suggesting they may be monthly funding increments under a larger managed care program rather than standalone awards. The highest-conviction signal is a single bullish rating on the $572M February 2026 order, but the overall neutral-to-bullish tone is tempered by the lack of outlayed funds, compressed performance windows, and absence of options or extensions. Key watch items include whether the VA exercises follow-on task orders and whether UnitedHealth Group recognizes revenue from these contracts in Q1 2026 earnings.

9 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 30, 2026

The July 30, 2026, batch of 50 filings is dominated by a single, massive event: BlackRock, Inc. filed a wave of 13G and 13G/A disclosures, revealing a broad, passive rebalancing of its portfolio across 49 companies. The key theme is not activist intent but a systematic deployment of capital, with BlackRock increasing stakes in 30+ companies, often by modest amounts (1-3% share count increases), while trimming a few positions. The most material outlier is a non-BlackRock activist filing: TOP Financial Group Ltd (SC 13D), where Chairwoman Junli Yang increased her beneficial ownership to 17.1% via a $12M warrant exercise, signaling strong insider conviction and potential control intent. Across the BlackRock filings, the most significant stakes are in Sarepta Therapeutics (15.8%), SolarEdge Technologies (15.2%), and Sunrun Inc. (14.7%), highlighting a thematic tilt toward renewable energy and biotech. The aggregate data shows no sector-wide distress, but rather a 'steady-state' accumulation pattern, with BlackRock's passive strategy reinforcing existing positions in small and mid-cap names. The lack of any activist campaigns or major institutional ownership changes outside of BlackRock's routine updates makes this batch a story of capital allocation by the world's largest asset manager, with the TOP Financial filing providing the only true 'activist' signal.

1 high priority 49 medium 50 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 30, 2026

This digest covers two HHS/BARDA contracts totaling $124.3 million, both civilian biodefense R&D awards with no defense-related content. The dominant theme is pandemic/radiation preparedness, with BARDA as the sole agency. The highest-conviction signal is OSSIUM HEALTH's $61 million cost-sharing contract for bone marrow cryo-banking (potential $122 million with options through 2029), which offers multi-year revenue visibility but carries execution risk from cost-sharing. A key risk is CANGENE CORPORATION's $63.3 million BARDA award from 2013 showing $0 in outlays, suggesting possible non-performance or data staleness that could signal contract management issues at BARDA. No bullish or bearish signals were identified; both contracts are neutral.

2 total filings